CIK 0001095981 · Non-accelerated filer<br>Smaller reporting company
CERENOME, INC.
Sign in to watch- Ticker
- CNSY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330827593
- Phone
- 737.255.7194
- Business address
- 6420 LEVIT GREEN BOULEVARD, SUITE 310, HOUSTON, TX, 77021
- Former names
- PLUS THERAPEUTICS, INC., CYTORI THERAPEUTICS, INC., MACROPORE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-11-28 | Hawkins Richard J Director | Option exercise · Subscription Rights (Right to Buy) | −3 | 0 | ||
| 2017-11-28 | Hawkins Richard J Director | Option exercise · Series B Preferred Stock | +3 | 3 | ||
| 2017-11-28 | Hawkins Richard J Director | Option exercise · Warrants (Right to Buy) | +5,400 | 5,400 | ||
| 2017-11-28 | HARRIS JOHN DAVID VP and GM Cell Therapy | Option exercise · Subscription Rights (Right to Buy) | −1 | 0 | ||
| 2017-11-28 | HARRIS JOHN DAVID VP and GM Cell Therapy | Option exercise · Series B Preferred Stock | +1 | 1 | ||
| 2017-11-28 | HARRIS JOHN DAVID VP and GM Cell Therapy | Option exercise · Warrants (Right to Buy) | +1,800 | 1,800 | ||
| 2017-11-28 | Girao Tiago VP & Chief Financial Officer | Option exercise · Subscription Rights (Right to Buy) | −1 | 0 | ||
| 2017-11-28 | Girao Tiago VP & Chief Financial Officer | Option exercise · Series B Preferred Stock | +1 | 1 | ||
| 2017-11-28 | Girao Tiago VP & Chief Financial Officer | Option exercise · Warrants (Right to Buy) | +1,800 | 1,800 | ||
| 2017-05-22 | LAPOINTE ANTHONY GREGG Director | Grant or award · Non-Qualified Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2017-03-08 | Marino Mark Chief Medical Officer | Grant or award · Incentive Stock Option (right to buy) | +31,100 | 31,100 | ||
| 2017-03-08 | HEDRICK MARC H President and CEO | Grant or award · Incentive Stock Option (right to buy) | +96,350 | 96,350 | ||
| 2017-03-08 | HAYDEN JEREMY B. General Counsel & VP of BD | Grant or award · Incentive Stock Option (right to buy) | +31,100 | 31,100 | ||
| 2017-03-08 | HARRIS JOHN DAVID VP and GM Cell Therapy | Grant or award · Incentive Stock Option (right to buy) | +31,100 | 31,100 | ||
| 2017-03-08 | Girao Tiago VP & Chief Financial Officer | Grant or award · Incentive Stock Option (right to buy) | +31,100 | 31,100 | ||
| 2017-03-08 | Marino Mark Chief Medical Officer | Grant or award · Incentive Stock Option (right to buy) | +42,000 | 42,000 | ||
| 2017-03-08 | HEDRICK MARC H President and CEO | Grant or award · Incentive Stock Option (right to buy) | +130,200 | 130,200 | ||
| 2017-03-08 | HAYDEN JEREMY B. General Counsel & VP of BD | Grant or award · Incentive Stock Option (right to buy) | +42,000 | 42,000 | ||
| 2017-03-08 | HARRIS JOHN DAVID VP and GM Cell Therapy | Grant or award · Incentive Stock Option (right to buy) | +42,000 | 42,000 | ||
| 2017-03-08 | Girao Tiago VP & Chief Financial Officer | Grant or award · Incentive Stock Option (right to buy) | +42,000 | 42,000 |
Page 13 of 53 · 1,048 trades